Ipsen Expands Pact with Exelixis To Develop Cabometyx

Ipsen, a worldwide biopharmaceutical firm with an emphasis on getting groundbreaking medicines to patients in three remedial regions: oncology, interesting sickness and neuroscience, has reported confirmation of an extended partnership and license agreement with Exelixis, Inc. for the improvement of Cabometyx (cabozantinib) in cutting edge pancreatic neuroendocrine tumours (pNETs) and high level extra-pancreatic neuroendocrine tumours (epNETs).

The CABINET phase III trial, which examined Cabometyx versus placebo in individuals with advanced pNETs or advanced epNETs whose disease had progressed after prior systemic therapy, was led by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute (NCI). The agreement is based on the positive results of the trial. An autonomous Data and Safety Monitoring Board suggested to stop accrual to the study, unblind patients and permit hybrid from placebo to Cabometyx. This was because of early viability shown at an interim analysis in both of the trial’s cohorts, with clinically significant upgrades in progression-free survival (PFS).

“With many people diagnosed with neuroendocrine tumours at an advanced stage of disease and treatment options limited upon progression, the need for efficacious new therapies is extensive,” said Christelle Huguet, EVP and head of research and development, Ipsen. “The positive results demonstrated for Cabometyx within the CABINET phase III trial represent clinically meaningful improvements in progression-free survival at a challenging stage of disease where there are few or no available treatment options. We look forward to discussing these clinical findings with regulatory authorities.”